A 24-week randomized trial of controlled-release physostigmine in patients with Alzheimer's disease

Neurology

Volumn 52, Issue 6, 1999, Pages 1146-1152

  Thal, Leon J ^a,f   Ferguson, J M ^b   Mintzer, J ^c   Raskin, A ^d   Targum, S D ^e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Pharmacology Research Corporation   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^d Valley Village Professional Center   (United States)

^e CROZER CHESTER MEDICAL CENTER   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATROPINE; DONEPEZIL; METRIFONATE; PHYSOSTIGMINE; RIVASTIGMINE;

AGITATION; ALZHEIMER DISEASE; ARTICLE; ASTHENIA; CLINICAL TRIAL; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DYSPNEA; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERHIDROSIS; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OUTCOMES RESEARCH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SWEATING; VERTIGO;

EID: 0032921029     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.52.6.1146     Document Type: Article

References (24)

1. Perry EK, Tomlinson BE, Blessed G, Bergmann K, Gibson PH, Perry RH. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. BMJ 1978;2:1457-1459.
2. Francis PT, Plamer AM, Sims NR, et al. Neurochemical studies of early-onset Alzheimer's disease: possible influence on treatment. N Engl J Med 1985;313:7-11.
3. Davies P, Maloney AJF. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 1976;2:1403.
4. Whitehouse PJ, Price DL, Clark AW, Coyle JT, DeLong MR. Alzheimer's disease: evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann Neurol 1981;10:122-126.
5. Perry EK, Tomlinson BE, Blessed G, Bergman K, Gibson PH, Perry RH. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. BMJ 1978; 2:1457-1459.
6. Knapp MJ, Knopman DS, Solomon PR, et al. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA 1994;271:985-991.
7. Thai LJ, Schwartz G, Sano M, et al. A multicenter double-blind study of controlled-release physostigmine for the treatment of symptoms secondary to Alzheimer's disease. Neurology 1996;47:1389-1395.
8. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT, the Donepezil Study Group. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology 1998;50:136-145.
9. Bartus RT. Evidence for a direct cholinergic involvement in the scopolamine-induced amnesia in monkeys: effects of concurrent administration of physostigmine and methylphenidate with scopolamine. Pharmacol Biochem Behav 1978;9:833-836.
10. Dekker AJAM, Connor DM, Thai LJ. The role of cholinergic projections from the nucleus basalis in memory. Neurosci Biobehav Rev 1991;15:299-317.
11. Thai LJ, Masur DM, Blau AD, Fuld PA, Klauber MR. Chronic oral physostigmine without lecithin improves memory in Alzheimer's disease. J Am Geriatr Soc 1989;37:42-48.
12. Mohs RC, Davis BM, Johns CA, et al. Oral physostigmine treatment of patients with Alzheimer's disease. Am J Psychiatry 1985;142:28-33.
13. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Standlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944.
14. Folstein MF, Folstein SE, McHugh PR. "Mini-Mental State": a practical method for grading on the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12:189-198.
15. Rosen WG, Terry RD, Fuld PA, et al. Pathological verification of ischemic score in differentiation of dementias. Ann Neurol 1980;7:486-488.
16. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967;6:275-296.
17. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984;141:1356-1364.
18. Knopman DS, Knapp MJ, Gracon SI, Davis CS. The Clinician Interview-Based Impression (CIBI): a clinician's global change rating scale in Alzheimer's disease. Neurology 1994;44:2315-2321.
19. Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 1969;9:179-186.
20. Clinical global impressions. In: Guy W, ed. ECDEU assessment manual for psychopharmacology. Rev. ed. Department of Health, Education and Welfare publication no. (ADM) 76-338. Rockville, MD: Department of Health, Education and Welfare, 1976:218-222.
21. Schwartz GE. Development and validation of the Geriatric Evaluation by Relative Rating Instrument (GERRI). Psychol Rep 1983;53:479-488.
22. CPMP European Public Assessment Report (EPAR) for Exelon. CPMP/243/98. May 12, 1998.
23. Morris JC, Cyrus PA, et al. Effects of metrifonate on the cognitive, global and behavioral function of Alzheimer's disease patients: results of a randomized, double-blind, placebo-controlled study. Neurology 1998;50:1222-1230.
24. Bodick NC, Offen WW, Levey AI, et al. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer's disease. Arch Neurol 1997;54:465-473.